## **Core Concept**
The question tests knowledge of monoclonal antibodies used for therapeutic purposes, specifically those targeting anthrax toxin. Anthrax is caused by *Bacillus anthracis*, and its toxin is a critical virulence factor. Monoclonal antibodies are laboratory-made molecules engineered to serve as substitute antibodies that can restore, enhance, or mimic the immune system's attack on cells.

## **Why the Correct Answer is Right**
The correct answer, **.**, refers to a specific monoclonal antibody designed to neutralize anthrax toxin. This involves understanding that anthrax toxin acts through a complex mechanism involving protective antigen (PA), lethal factor (LF), and edema factor (EF). The monoclonal antibody likely targets one of these components to prevent toxin internalization and subsequent cell death. For anthrax, the therapeutic approach often involves targeting the protective antigen (PA) component of the toxin.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because it does not correspond to the correct monoclonal antibody targeting anthrax toxin. Without the specific details of each option, we can infer that A is not the therapeutic agent for anthrax.
- **Option B:** Similarly, this option is incorrect as it does not represent the monoclonal antibody used for neutralizing anthrax toxin.
- **Option D:** This is also incorrect for the same reason; it does not accurately represent the therapeutic monoclonal antibody for anthrax.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that **Raxibacumab** is a monoclonal antibody used for the treatment of inhalational anthrax. It works by targeting the protective antigen (PA) of the anthrax toxin, preventing the toxin from entering host cells. This is a critical piece of information for managing bioterrorism-related illnesses and for those preparing for postgraduate medical exams.

## **Correct Answer Line**
**Correct Answer: C.**